Wells Fargo Van Kasper Growth Stock Conference The Wyndham Emerald Plaza San Diego, California
June 18, 2001 - 9:30 a.m.
Amylin Pharmaceuticals, Inc.
Safe Harbor Statement
Current Pipeline Status
Diabetes:Worldwide Estimates and Projections
Diabetes:A Serious, Progressive Disease
Diabetes:Devastateing Clinical and Economic Consequences
Diabetes:Inadequately Treated and Growing Rapidly
Lessons from Landmark Diabetes Studies:Intervention Works
Lessons from Landmark Diabetes Studies:Intervention Works, But at a Price #1
Lessons from Landmark Diabetes Studies:Intervention Works, But at a Price #2
SYMLIN™ (pramlintide acetate)Overview
SYMLIN Patient FocusPeople With Diabetes Who Use Insulin
SYMLIN™ (pramlintide acetate)Glucose and Weight Effect at One Year
SYMLIN Market OpportunityNorth America and Western Europe
SYMLIN Market OpportunityUnited States
SYMLIN Market Opportunity: US Insulin Prescriptions Highly Concentrated
SYMLIN Commercial OperationsSales Planning Model
SYMLIN Commercial OperationsExperienced Core Commercial Team
Amylin the HormoneMedical Education Program
Upcoming Medical Meetings
AC2993 (synthetic exendin-4)Overview
AC2993 (synthetic exendin-4)Patient Focus
AC2993 (synthetic exendin-4)
AC2993 LAR
Potential Diabetes Target Markets
AC3056
Expanding the Pipeline
Financial Overview
Goals for 2001